Swedish pharmaceutical company Camurus (STO:CAMX) announced on Thursday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa, octreotide subcutaneous depot, for maintenance treatment in adult patients with acromegaly, a rare, progressive disease, typically caused by a tumour of the pituitary gland, who have responded to and tolerated treatment with somatostatin analogues.
The MHRA's marketing authorisation for Oczyesa is based on the results from a comprehensive clinical programme which comprised seven clinical studies.
Oczyesa is formulated using Camurus' proprietary FluidCrystal technology. It is designed for convenient once-monthly, subcutaneous self-administration using a pre-filled autoinjector pen with a hidden, thin needle.
Oczyesa was granted marketing authorisation in the European Union by the European Commission on 30 June 2025.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval